Abstract
Shares in WuXi Biologics surged 39% on June 13, its first day of trading on the Hong Kong Stock Exchange. The company, a Chinese contract researcher and manufacturer of antibody-drug conjugates and other biological drugs, raised more than $500 million from its initial public offering. WuXi Biologics is a subsidiary of the giant contract research firm WuXi AppTec, which delisted from the New York Stock Exchange in 2015 after a management buyout. At the time, WuXi’s Chair Ge Li said he did not intend to relist the company on a stock exchange in China.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
